Phase 3, Randomized, Safety, Lot Consistency and Clinical Benefit Study of Recombinant Botulinum Vaccine A/B

Summary

This Phase 3 clinical trial is a double blind, placebo-controlled, randomized, multicenter investigation of rBV A/B in male and female healthy adults 18 to 55 years of age.

Timeline

Start

2017-10

Primary completion

2019-03

Completion

2019-09

Outcome

Outcome not reported

Stopped (Business): “Sponsor decision due to product manufacturing and redesign of clinical trial.”

Drugs

Indications